Emcure Pharmaceuticals Limited (NSE: EMCURE) stock price moves up 5% intraday to ₹1884.0, clearing its 6M resistance trendline in a breakout move.
Emcure Pharmaceuticals Limited (EMCURE) reports strong FY26 results with revenue up 16.6% and margin expansion, driven by robust international performance.
Emcure Pharmaceuticals Limited shows robust Q4 FY26 results with 16.6% revenue growth and strategic portfolio expansion.
Emcure Pharmaceuticals Limited reports strong Q4 FY26 results with 16.7% revenue growth and 19.7% EBITDA margin.
